1. Home
  2. VS vs ENVB Comparison

VS vs ENVB Comparison

Compare VS & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

N/A

Current Price

$1.07

Market Cap

7.9M

Sector

Technology

ML Signal

N/A

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

N/A

Current Price

$1.46

Market Cap

6.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VS
ENVB
Founded
2013
1994
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
6.7M
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
VS
ENVB
Price
$1.07
$1.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.5K
★ 56.4K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 75.97
N/A
EPS
★ N/A
N/A
Revenue
$2,183,415.00
★ $39,914,675.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3711.30
N/A
52 Week Low
$0.75
$0.57
52 Week High
$2.47
$13.25

Technical Indicators

Market Signals
Indicator
VS
ENVB
Relative Strength Index (RSI) 40.85 47.10
Support Level $1.01 $1.17
Resistance Level $1.18 $1.53
Average True Range (ATR) 0.06 0.09
MACD 0.00 -0.01
Stochastic Oscillator 19.13 18.86

Price Performance

Historical Comparison
VS
ENVB

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: